Abstract |
In a randomized, multicenter trial, nizatidine 150 mg or 300 mg, or placebo, was administered twice daily for six weeks to 515 patients with gastroesophageal reflux disease ( GERD). Gelusil antacid tablets were taken as needed for pain. Significantly superior rates of endoscopically proven complete healing (normal-appearing mucosa) versus placebo occurred after three weeks with nizatidine 150 mg, and after six weeks with nizatidine 300 mg. Six-week healing rates were 38.5% for nizatidine 300 mg, 41.1% for nizatidine 150 mg, and 25.8% for placebo. The nizatidine 150 mg treatment group had significantly greater improvement in daytime and nighttime heartburn severity after one day of therapy versus placebo. Twice-daily administration of nizatidine 150 mg or 300 mg provides prompt relief from the major symptom of GERD, heartburn, and complete healing of esophagitis is seen in many patients.
|
Authors | M L Cloud, W W Offen |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 37
Issue 6
Pg. 865-74
(Jun 1992)
ISSN: 0163-2116 [Print] United States |
PMID | 1587191
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Double-Blind Method
- Esophagitis, Peptic
(diagnosis, drug therapy)
- Esophagoscopy
- Female
- Gastroesophageal Reflux
(diagnosis, drug therapy)
- Heartburn
(prevention & control)
- Humans
- Male
- Middle Aged
- Nizatidine
(therapeutic use)
- Time Factors
- Wound Healing
|